Trials / Completed
CompletedNCT00992238
A Relative Bioavailability Study of 100 mg Flavoxate Hydrochloride Tablets Under Fasting Conditions
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (planned)
- Sponsor
- Padagis LLC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to compare the relative bioavailability of Flavoxate Hydrochloride tablets 100mg manufactured by Paddock Laboratories, Inc., with that of Urispas® tablets 100mg by SmithKline Beecham Pharmaceuticals under fasting conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Flavoxate Hydrochloride Tablets, 100mg | |
| DRUG | Urispas® Tablets, 100mg |
Timeline
- First posted
- 2009-10-09
- Last updated
- 2023-07-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00992238. Inclusion in this directory is not an endorsement.